Neumora Therapeutics is trading at $0.47, with a -10.32% move, as biotech-sector weakness may be contributing to the October 6 decline; no verified company-specific announcement or new catalyst was identified. - Supplied sector context reports XBI down 2.50%, while the broad market is higher; XBI was also reported lower during the session. - Available company news is older, and the sector backdrop does not establish the cause of Neumora Therapeutics’ larger move.